What is the cause of treatment-related morbidity in immune thrombocytopenic purpura (ITP)?

Updated: Apr 22, 2018
  • Author: Craig M Kessler, MD, MACP; Chief Editor: Srikanth Nagalla, MBBS, MS, FACP  more...
  • Print
Answer

Treatment-related morbidity may result from the need to maintain the platelet count in a safe range in patients with chronic treatment-resistant ITP. These patients may require a long-term course of corticosteroids, other immunosuppressive medications, or splenectomy, and thus may experience the complications of therapy with corticosteroids or splenectomy.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!